Chronic liver diseases H. pylori infection
Conditions
Interventions
Patients will orally receive triple therapy with 30mg lansoprazole, 750mg amoxicillin, and 250mg clarithromycin twice a day for seven days
Sponsors
Osaka City University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with chronic liver diseases 2. Patients with hepatic complications such as thrombocytopenia and hyperammonemia 3. Patients with H. pylori-related atrophic gastritis other upper gastrointestinal diseases diagnosed endoscopy
Exclusion criteria
Exclusion criteria: 1. Patients with history of hypersensitivity to lansoprazole, amoxicillin, and clarithromycin. 2. Patients being treated with atazanavir, rilpivirine, pimozide, preparation containing ergotamine and tadalafil. 3. Patients with liver or kidney diseases being treated with colchicine. 4. Patients with infectious mononucleosis. 5. Patients with severe renal impairment. 6. Woman during the first three months of pregnancy. 7. Patients whom the principal and/or sub-investigators judged inadequate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in platelet counts after eradication of H. pylori | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in blood ammonia levels after eradication of H. pylori | — |
Countries
Japan
Contacts
Public ContactMasaru Enomoto
Osaka City University Graduate School of Medicine Department of Hepatology
Outcome results
None listed